39 results on '"VanDevanter, D.R."'
Search Results
2. Antipseudomonal treatment decisions during CF exacerbation management
3. Building global development strategies for cf therapeutics during a transitional cftr modulator era
4. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)
5. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa
6. Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis
7. Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact.
8. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis
9. Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials
10. Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint
11. P096 Effect of acute systemic corticosteroids on clinical outcomes in cystic fibrosis pulmonary exacerbations
12. WS03.05 Multicenter validation of the cystic fibrosis-ABLE score as a predictor of outcome and therapeutic response in cystic fibrosis
13. WS01.01 Antipseudomonal treatment decisions during cystic fibrosis exacerbation management
14. Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis.
15. Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.
16. P094 Design, enrollment, and feasibility of the STOP-2 randomised study of intravenous antibiotic treatment duration in cystic fibrosis pulmonary exacerbations
17. EPS7.7 Microbiologic changes in CF patients with chronic P. aeruginosa airway infection after 6 cycles of inhaled levofloxacin
18. 37 Microbiologic changes observed over 6 months in a randomized, open-label comparison of inhaled levofloxacin and inhaled tobramycin in persons with cystic fibrosis and chronic P. aeruginosa (Pa) airway infection
19. 38 History of pulmonary exacerbations (PEx) as a predictor of response to nebulized levofloxacin compared with nebulized tobramycin
20. WS23.4 IV antibiotic treatment of
21. 311 Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis
22. 188 Standardized treatment of pulmonary exacerbations (STOP) study: Clinical presentations of pulmonary exacerbations
23. 189 Standardized treatment of pulmonary exacerbation (STOP) study: Symptomatic treatment response
24. 186 Manifestation and progression of illness in young children with cystic fibrosis: A targeted literature review
25. 117 Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis clinical trials
26. WS07.1 Standardized treatment of pulmonary exacerbations (STOP) study: Treatment goals for pulmonary exacerbations
27. WS7.6 Incorporation of a third inhaled antipseudomonal antibiotic class into the management of patients at an adult CF care center
28. WS3.4 Lack of correlation between sputum Pseudomonas aeruginosa density and FEV1 changes among CF patients treated with inhaled antibiotics
29. Important steps in the journey to highly effective CFTR modulator access for people with CF
30. WS12.1 Evidence of diminished FEV1 in CF 6-year-olds followed in the European CF registry, 2007–2009
31. Another step in the journey: From CFTR mutation to sweat chloride concentration to survival
32. 337 Changing incidence and thresholds for pulmonary exacerbation treatment, North America 1995-2005
33. 180 Choice of IV vs. non-IV antibiotics for treating pulmonary exacerbations in patients with cystic fibrosis
34. WS24.5 Unresponsive patients benefit from switching intravenous antibiotic treatments for pulmonary exacerbation
35. Sample size estimation for CF clinical trials using rate of lung function decline (RLFD) as an efficacy endpoint
36. 59. In vitro assessment of bactericidal activity and relevance to pharmacodynamics of aerosolized antibiotics
37. WS12.1 Evidence of diminished FEV1 in CF 6-year-olds followed in the European CF registry, 2007–2009.
38. Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation.
39. Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.